Member Info for johnlaycock

Https://www.linkedin.com/posts/oxford-biodynamics_happy-to-share-that-most-viewed-papers-activity-7122522116339507200-qdGP?utm_source=share&utm_medium=member_android

Nope sells

Stocksaint....what's the pont of your post? What value does it add to this discussion board. No one cares about your continued trashing of the company.

This is the link to the Innovate UK Transparency data

https://www.ukri.org/publications/innovate-uk-funded-projects-since-2004/

If you go into the excel spreadsheet and search for genedrive you will find details of all the Devote projects and the grant of 188k to Genedrive (line 4762 on the spreadsheet).

Key is as Mr Cheek says, its avoid direct costs and gives them access to patients .

GDR will receive c 200k direct - the rest is to UoM.

Let's hope we receive some positive news soon from todays NICE stroke review committee meeting.I

Roger65...if they are thinking of a placing, won't they want to spike the SP beforehand?

This is the link to the Innovate UK Transparency data

https://www.ukri.org/publications/innovate-uk-funded-projects-since-2004/

If you go into the excel spreadsheet and search for genedrive you will find details of all the Devote projects and the grant of 188k to Genedrive (line 4762 on the spreadsheet).

Because its available information on the UKVI website!

In any forward planning of the companies revenue / income, DEVOTE funding will not be part of it (say a max of 200k). The funding value (still to be publicly announced) is 'in-kind' so will not be going anywhere near the companies bank account. The vast bulk of the 4.2m devote programme will be going straight to the Uni of Manchester.

Erm isn't the clue 'to support FURTHER drawdown?

Why is all this buying going on if there is about to be a placing?

They've appointed a serious big hitter now as CEX. Do you think he would have accepted the role if he thought the company didn't have a great future?

If you hate to say it, why say it at all?

If the company announced 'significant sales' why would they then need funding?

His LinkedIn profile for the company specifically mentions his role is to improve the share price amongst other things. He looks to be the perfect match for the company on their road to profitability and successful commercialisation of the two products.

I guess this news also puts to bed all the talk of a imminent take over!

Am fully expecting soon the company to update on the stroke rollout/ devote funding details.

Plus we are due month the Nice report on stakeholder feedback delayed from July.

Hi to clarify....devote funding is 4.1m for three projects, of which Genedrive is 1. The company will receive very little direct funding (c200k) as the vast bulk will go to the University of Manchester. But this is brilliant news on the runway to commercialisation.